ACS Medicinal Chemistry Letters

PATENT HIGHLIGHT

pubs.acs.org/acsmedchemlett

Aminoquinoline Derivatives as HCV Inhibitors

Jean-Francois Brazeau[†] and Gerard Rosse*[,†,‡]

[†]Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States

[‡]Adjunct Associate Professor, Department of Pharmacology and Physiology, College of Medicine, Drexel University, New College Building, 245 North 15th Street, Philadelphia, Pennsylvania 19102, United States

Title:	Aminoquinoline derivatives as HCV inhibitors		
Patent/Patent Application Number:	WO 2013090929	**Publication date:**	Jun 20, 2013
Priority Application:	US 2011-576278P	**Priority date:**	Dec 15, 2011
Inventors:	Cai, Z. R.; Du, Z.; Ji, M.; Jin, H.; Kim, C. U.; Li, J.; Phillips, B. W.; Pyun, H.-J.; Saugier, J. H.		
Assignee Company:	Gilead Sciences, Inc., USA		
Disease Area:	HCV infection	**Biological Target:**	
Summary:	The application claims new aminoquinoline derivatives that may provide a treatment against HCV infections.		
Important Compound Classes:			

Key Structures:



Compound 4



Compound 25



Compound 5



Compound 105

Biological Assay: The HCV replicon assay was developed using cell line HCV subgenomic RNA derived from GT1a, GT1b, and GT2a.

Pharmacological Data: Over 180 compounds were tested for antiviral activity in HCV replicon assay. The unit for the EC_{50} is not described.

	HCV replicon assay – GT1a (EC_{50})	HCV replicon assay – GT1b (EC_{50})	HCV replicon assay – GT2a (EC_{50})
Compound **4**	0.060	0.076	9.423
Compound **5**	0.071	0.221	130.71
Compound **25**	0.028	0.064	25.750
Compound **105**	0.951	1.306	753.840

Synthesis: Over 180 compounds were prepared.

AUTHOR INFORMATION

Corresponding Author

*E-mail: grosse@dartneuroscience.com.

Notes

The authors declare no competing financial interest.

Special Issue: HCV Therapies

Received: September 18, 2013
Published: September 24, 2013